CareLit Fachartikel
Is Sorafenib an acceptable treatment possibility for patients with advanced hepatocellular carcinoma?
D Bettinger, M Schultheiß, E Knüppel, R Thimme, HE Blum, HC Spangenberg · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Dokument
867200
CareLit-ID
Jahr
2012
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Aims: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with an increasing incidence. For patients with advanced HCC Sorafenib is the treatment of choice since the SHARP study showed a survival benefit however daily clinical experience suggests that Sorafenib is much less effective than described in the SHARP study. Methods: Retrospectively, we analyzed 112 patients with advanced HCC treated with Sorafenib comparing overall survival (OS), time to progression (TTP) and frequency of adverse events of our study cohort with those of the SHARP and Asia – Pacific study. Patients receiving transa…
Schlagworte
Sorafenib treatment
advanced hepatocellular carcinoma
Asia
Tumor
Apoptosis
Diarrhea
Zeitschrift für Gastroenterologie
